Promising Phase II data and a flurry of deal-making indicate that bispecific platform technologies are about to take antibodies to the next level.
Enjoying our latest content?
Log in or create an account to continue
- Access the most recent journalism from Nature's award-winning team
- Explore the latest features & opinion covering groundbreaking research
or
Rights and permissions
About this article
Cite this article
Holmes, D. Buy buy bispecific antibodies. Nat Rev Drug Discov 10, 798–800 (2011). https://doi.org/10.1038/nrd3581
Published:
Issue date:
DOI: https://doi.org/10.1038/nrd3581
